Skip to main content

Table 1 Clinical characteristics of subjects studied

From: Citrullinated histone H3, a marker of extracellular trap formation, is increased in blood of stable asthma patients

 

Asthma n = 60

Controls n = 50

p-value

Age, years

50 (39–56)

45.5 (39–53)

NS

Female gender

44 (73.7)

29 (58.0)

NS

Height, m

1.63 (1.58–1.71)

1.65 (1.6–1.76)

NS

Body mass index (BMI), kg/m2

26.9 (23.4–31.6)

26.4 (23.0–28.1)

NS

History of smoking

18 (30.0)

17 (34.0)

NS

Active smokers

7 (11.7)

8 (16.0)

NS

Arterial hypertension

27 (45.0)

16 (32.0)

NS

Diabetes mellitus

8 (13.3)

5 (10.0)

NS

Hypercholesterolemia

17 (28.3)

16 (32.0)

NS

Medications used:

 Inhaled corticosteroids

59 (98.3)

  

 Long-acting β2-agonists

49 (81.7)

  

 Montelukast

9 (15.0)

  

 Oral corticosteroids

17 (28.3)

  

Atopy

41 (68.3)

  

Asthma duration, years

10 (5–15)

  

Asthma control (according to Asthma Control Test results)

 Well-controlled (score > 19)

15 (25.0)

  

 very poorly controlled (score > 16)

25 (41.7)

  

Asthma severity (GINA):

 Mild

9 (15.0)

  

 Moderate

21 (35.0)

  

 Severe

30 (50.0)

  

Prebronchodilator FEV1/VC, %

67.8 (59.4–75.9)

  

Postbronchodilator FEV1/VC, %

73.1 (68.2–79.7)

  

Postbronchodilator TLC, L

[% of predicted value]

5.76 (5.18–6.47)

[111.8 (103.3–119.8)]

  

Postbronchodilator RV, L

[% of predicted value]

2.23 (1.67–2.66)

[123.6 (108.3–147.2)]

  
  1. Categorical variables are presented as numbers (percentages), continuous variables as median (interquartile range)